Dexcom Archives - Page 3 of 14 - Medical Design Sourcing

Dexcom, RxFood partner on AI-based nutrition, glucose monitoring for diabetes management

Within the RxFood app, Dexcom CGM users can capture photos of their meals. It eliminates the need for manual food and nutrition tracking. [Image courtesy of RxFood/Dexcom]Dexcom (Nasdaq:DXCM) announced that it teamed up with RxFood on a digital diabetes solution for people in Canada.

The first-of-its-kind partnership combines Dexcom’s continuous glucose monitoring (CGM) with RxFood’s AI-driven personalized nutrition assessments. The companies aim to introduce an improved digital health solution for people living with diabetes. It integrates food data with insulin dosing, exercise and glucose information.

RxFood made its next-generation app, featuring Dexcom CGM data integration, now available to healthcare program stakeholders in Canada. That includes clinics, hospitals, health authorities, pharmacies, insurers and employers. Through these programs, Canadians using the Dexcom G6 or G7 (once available) can access combined food and glucose data. It offer…

Dexcom One CGM sensor launches in France with reimbursement

The Dexcom One platform. [Image from Dexcom]Dexcom (Nasdaq: DXCM) + recently announced the availability of its Dexcom One real-time continuous glucose monitor (CGM) in France.

The availability of the real-time CGM sensor comes via reimbursement. It brings the technology to half a million more people with diabetes in France. The company secured access to the platform for all patients two years and older with type 1 and type 2 diabetes undergoing intensive insulin therapy.

Get the full story at our sister site, Drug Delivery Business News.

Analysts: GLP-1 drugs should have minor impact on insulin pump market — but will boost CGMs

From left: the Insulet Omnipod 5, Medtronic MiniMed 780G and the Senseonics Eversense E3. These technologies could be among those affected by the rise of the GLP-1 drug class. [Images courtesy of Insulet, Medtronic and Senseonics]Based on conversations with diabetes experts, analysts are playing down the potentially negative impact of GLP-1 receptor agonists on the diabetes technology industry.

The GLP-1 drug class, which includes Ozempic and Wegovy, has cast a shadow of doubt over diabetes technology of late. This therapeutic class, a glucagon-like peptide 1, has proven to lead to improved blood sugar control and weight loss.

In addition to the popular therapeutics, some companies — like i20 Therapeutics and Vivani Medical — are developing long-term implants that elute GLP-1s.

Positive clinical results from these drugs led to some negative market movement for a few of the biggest names in diabetes technology. Analysts even recently trimmed some forecasts o…

Dexcom appoints a new board director

New Dexcom board director Rimma Driscoll. [Image from Zoetis]Dexcom (Nasdaq: DXCM) + announced today that it appointed Rimma Driscoll to its board of directors.

The San Diego-based continuous glucose monitor (CGM) maker made Driscoll’s appointment effective on Aug. 24. She currently serves as EVP and head of global strategy, commercial and business development and global biodevices for Zoetis.

At Zoetis, a leading animal health company and a Fortune 500 member, Driscoll oversees the global business strategy. She manages the execution of commercial launch plans, external business development and integration efforts.

Get the full story at our sister site, Drug Delivery Business News.

Dexcom more than doubles profits on 25% sales growth in Q2

Dexcom (Nasdaq:DXCM) shares ticked up after hours on second-quarter results that topped the consensus forecast.

Shares of DXCM rose 2.3% at $132.35 apiece after the market closed today. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — closed the day down 0.6%.

The San Diego-based continuous glucose monitor (CGM) maker posted profits of $115.9 million. That equals 28¢ per share on sales of $871.3 million for the three months ended June 30, 2023.

Dexcom more than doubled its profits on sales growth of 25.2%.

Get the full story at our sister site, Drug Delivery Business News.

Dexcom CCO Teri Lawver says new sensor is ‘first step’ to expand addressable market

New Dexcom CCO Teri Lawver. [Image from Janssen Pharmaceutical Company website]Teri Lawver joined Dexcom (Nasdaq:DXCM) + as chief commercial officer just as the company got set for a massive commercial undertaking.

The FDA cleared the company’s next-generation Dexcom G7 continuous glucose monitor (CGM) in December 2022. One month later, Lawver assumed the position of CCO. Within about a month, she was set to oversee the U.S. launch of the G7.

A former Johnson & Johnson executive, Lawver became the first to serve in Dexcom’s newly created CCO role. As she assumed the position amid a crucial time for the company, she observed what makes Dexcom one of the leaders in the diabetes technology space — and potentially beyond.

“The first few months I’ve just reaffirmed the reasons that I joined Dexcom,” Lawver told Drug Delivery Business News. “It’s an unmatched opportunity for …

The biggest stories from the American Diabetes Association (ADA) 2023 Scientific Sessions

From left: the Insulet Omnipod 5, Medtronic MiniMed 780G and the Senseonics Eversense E3. These technologies were part of some of the biggest stories from the American Diabetes Associations’ 2023 Scientific Sessions. [Images courtesy of Insulet, Medtronic and Senseonics]

As it does every year, this past week, the American Diabetes Association convened its Scientific Sessions to bring together leaders in the diabetes space.

At last year’s event, next-generation technologies from the big hitters took the spotlight. The 83rd iteration this past week produced a range of new studies, product updates and positive news for a number of technologies and innovations. From continuous glucose monitors (CGMs) to insulin pumps to digital platforms and diabetes reversal procedures, ADA 2023 saw it all.

Usual suspects, like Dexcom, Abbott, Medtronic and Insulet shared their updates. Meanwhile, promising data came …

The biggest stories from the American Diabetes Association (ADA) 2023 Scientific Sessions

From left: the Insulet Omnipod 5, Medtronic MiniMed 780G and the Senseonics Eversense E3. These technologies were part of some of the biggest stories from the American Diabetes Associations’ 2023 Scientific Sessions. [Images courtesy of Insulet, Medtronic and Senseonics]As it does every year, this past week, the American Diabetes Association convened its Scientific Sessions to bring together leaders in the diabetes space.

At last year’s event, next-generation technologies from the big hitters took the spotlight. The 83rd iteration this past week produced a range of new studies, product updates and positive news for a range of technologies and innovations. From continuous glucose monitors (CGMs) to insulin pumps to digital platforms and diabetes reversal procedures, ADA 2023 saw it all.

Usual suspects, like Dexcom, Abbott, Medtronic and Insulet shared their updates. Meanwhile, promising data came out of Senseonics, Sernova, Bigfoot Biomedical and more.<…

Dexcom aims to bring new glucose sensor to the market for people who don’t use insulin

Dexcom (Nasdaq:DXCM) today unveiled its strategy to expand access to its glucose-sensing technology for millions around the world.

San Diego-based Dexcom held an Investor Day event in which it revealed plans to bring a new product to market in the U.S. in 2024. The company designed its new product for people who don’t use insulin — approximately 70% of Americans with diabetes.

Dexcom said it plans for its new product to feature a 15-day sensor and a cash-pay option. The company wants to offer a new software experience tailored for those not on insulin.

Earlier this year, Dexcom Chair, President and CEO, Kevin Sayer, hinted at potential new avenues when speaking to Drug Delivery Business News. He explained that the company wanted to broaden its focus, even revising its mission statement. Dexcom updated its mission — enabling people to take control of diabetes — by changing “diabetes” to “health.”

The top IVD innovation news stories of 2023 — so far

[Image courtesy of the National Cancer Institute via Unsplash]This year is proving to be another important year for innovation in the in vitro diagnostic (IVD) space.

According to the FDA, IVD devices are tests performed on samples taken from the human body. They could be everything from blood tests processed in labs to home COVID-19 or pregnancy tests to continuous glucose monitors using tiny sensors stuck under to skin to measure blood glucose — and much more.

Here are five IVD innovation stories that have caught our attention so far this year:

5. Hologic wins FDA clearance for COVID-flu-RSV assay

Last winter, the U.S. and other countries dealt with a “tripledemic” of COVID-19, influenza, and RSV. So it was welcome news in May when Hologic announced FDA 510(k) clearance of its Panther Fusion SARS-CoV-2/Flu A/B/RSV assay. The news came months after the FDA granted an emergency use authorization for a COVID/flu/RSV test from BD.

Read the full story a…

Dexcom study shows diabetes’ impact on mental health

The Dexcom G6. [Image courtesy of Dexcom]A new study commissioned by Dexcom (Nasdaq:DXCM) + found that diabetes has significant negative effects on mental health.

The study revealed that 84% of people surveyed agree that having diabetes can negatively impact mental health. It also demonstrated that nearly all participants (91%) believe technology enables a balanced lifestyle while managing diabetes.

Dexcom, a maker of continuous glucose monitor (CGM) technology, announced results ahead of the UK’s Diabetes Awareness Week. Censuswide conducted this research in April 2023 on behalf of the company. It included responses from 1,000 nationally representative UK respondents aged 16 years and up living with diabetes.

Get the full story at our sister site, Drug Delivery Business News.

Design firm Delve makes first acquisition under new owner

Delve developed a prototype of the SC360 proton-beam therapy system for ProNova. [Photo courtesy of Delve]

Delve announced its acquisition of Boston-based digital innovation and design firm Altr this week.

Madison, Wisconsin–based Delve said Altr is its first acquisition under the ownership of private equity firm Trinity Hunt Partners, which purchased Delve in May 2021 and merged it with product design consultancy firm Bresslergroup.

“Almost two years ago to the day, we announced our intention to build a company that could be considered the world’s best end-to-end product innovation firm,” Delve President Andrew Weiman said in a news release yesterday. “With Altr, we take another giant step forward. Much more to come.”

The deal comes as medical device developers are increasingly integrating digital offerings into their devices. Delve said the Altr deal “strength…